Bioventus Inc. (BVS) Income Statement
BVS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBVS revenue and net income
Where BVS's revenue goes
2025Each bar shows an amount and its share of revenue. BVS kept 4.0% of revenue as net income.
BVS profit margins
BVS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −0.9% | +3.5% | +12.1% | +8.4% |
| Gross profit | −1.5% | +4.9% | +10.4% | +7.9% |
| Operating income | — | — | +22.5% | — |
| Net income | — | — | +6.7% | — |
| EPS (diluted) | +44.7% | +62.0% | −21.9% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BVS quarterly EPS vs estimates
Bioventus beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: November 3, 2026 (estimate $0.17).
BVS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $568.1M | $573.3M | $512.3M | $512.1M | $430.9M | $321.2M | $340.1M | $319.2M | $292.1M | $274.5M |
| Cost of revenue | $185.7M | $185.1M | $184.2M | $181.0M | $128.2M | $87.6M | $90.9M | $84.2M | $92.1M | $91.4M |
| Gross profit | $382.4M | $388.2M | $328.2M | $331.1M | $302.7M | $233.5M | $249.2M | $235.0M | $200.0M | $183.1M |
| Research & development | $12.1M | $13.6M | $13.4M | $23.9M | $19.0M | $11.2M | $11.1M | $8.1M | $8.1M | $7.9M |
| Sales, general & admin | $314.0M | $327.1M | $303.9M | $332.1M | $254.3M | $193.1M | $198.5M | $191.7M | — | — |
| Total operating expenses | $323.9M | $400.2M | $409.9M | $498.3M | $290.6M | $212.3M | $218.0M | $209.5M | $172.9M | $168.2M |
| Operating income | $58.5M | −$12.0M | −$81.7M | −$167.2M | $12.1M | $21.2M | $31.2M | $25.5M | $27.0M | $14.9M |
| Interest expense | $26.5M | $38.8M | $40.7M | $12.0M | $1.1M | $9.8M | $21.6M | $19.2M | $18.9M | $15.9M |
| Income before taxes | $25.7M | −$49.1M | −$121.1M | −$189.0M | $9.5M | $15.9M | $9.7M | $6.1M | $8.7M | −$5.7M |
| Income taxes | −$1.6M | −$5.3M | $85,000 | −$44.4M | −$2.0M | $1.2M | $1.6M | $1.7M | −$785,000 | $1.1M |
| Net income | $22.7M | −$33.5M | −$156.2M | −$158.7M | $19.4M | $16.4M | $6.9M | −$12.2M | −$1.6M | −$18.0M |
| EBITDA | $99.2M | $39.2M | −$23.1M | −$121.6M | $45.5M | $54.3M | $61.6M | $54.5M | $59.8M | $44.0M |
| EPS (diluted) | $0.68 | $0.47 | −$2.48 | $0.16 | $0.82 | $2.34 | $0.12 | −$2.44 | −$0.33 | −$0.32 |
| Gross margin | 67.3% | 67.7% | 64.1% | 64.6% | 70.3% | 72.7% | 73.3% | 73.6% | 68.5% | 66.7% |
| Operating margin | 10.3% | −2.1% | −16.0% | −32.7% | 2.8% | 6.6% | 9.2% | 8.0% | 9.3% | 5.4% |
| Net margin | 4.0% | −5.9% | −30.5% | −31.0% | 4.5% | 5.1% | 2.0% | −3.8% | −0.6% | −6.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $153.2M | $132.1M | $157.9M | $138.7M | $147.7M | $123.9M | $153.6M | $139.0M | $151.2M | $129.5M | $135.4M | $120.8M |
| Cost of revenue | $47.5M | $42.4M | $50.4M | $45.8M | $47.0M | $42.4M | $51.0M | $45.4M | $47.6M | $41.1M | $49.1M | $41.9M |
| Gross profit | $105.7M | $89.7M | $107.5M | $92.8M | $100.7M | $81.5M | $102.7M | $93.6M | $103.6M | $88.4M | $86.3M | $78.8M |
| Research & development | $3.2M | $2.5M | $3.0M | $2.9M | $3.2M | $3.0M | $3.2M | $3.8M | $4.2M | $2.6M | $3.3M | $3.0M |
| Sales, general & admin | $82.7M | $78.3M | $82.8M | $78.7M | $79.1M | $73.5M | $86.6M | $81.1M | $94.8M | $78.4M | $78.4M | $69.8M |
| Total operating expenses | $86.5M | $80.8M | $85.8M | $80.7M | $82.0M | $76.5M | $94.7M | $89.5M | $135.1M | $83.5M | $85.1M | $76.4M |
| Operating income | $19.1M | $8.9M | $21.7M | $12.1M | $18.6M | $5.0M | $8.0M | $4.1M | −$31.5M | $4.9M | $1.2M | $2.4M |
| Interest expense | $4.1M | $4.3M | $5.3M | $6.2M | $7.5M | $7.5M | $9.0M | $9.5M | $9.9M | $10.3M | $10.3M | $10.1M |
| Income before taxes | $15.3M | $4.5M | $14.1M | $4.7M | $10.3M | −$3.4M | $232,000 | −$4.8M | −$41.6M | −$5.5M | −$8.4M | −$8.2M |
| Income taxes | −$20.9M | $571,000 | −$3.2M | $664,000 | $1.0M | −$95,000 | $550,000 | $589,000 | −$7.3M | $907,000 | −$750,000 | $600,000 |
| Net income | $33.4M | $3.1M | $14.8M | $3.2M | $7.5M | −$2.6M | −$156,000 | −$4.8M | −$25.7M | −$4.9M | −$6.1M | −$7.3M |
| EBITDA | $30.3M | $20.0M | $31.1M | $22.2M | $29.9M | $16.0M | $21.6M | $17.0M | −$18.5M | $16.6M | $14.3M | $15.8M |
| EPS (diluted) | $0.22 | $0.15 | $0.24 | $0.15 | $0.21 | $0.08 | $0.15 | $0.06 | $0.19 | $0.07 | $0.07 | $0.05 |
| Gross margin | 69.0% | 67.9% | 68.1% | 67.0% | 68.2% | 65.8% | 66.8% | 67.3% | 68.5% | 68.3% | 63.7% | 65.3% |
| Operating margin | 12.5% | 6.7% | 13.8% | 8.7% | 12.6% | 4.0% | 5.2% | 2.9% | −20.8% | 3.8% | 0.9% | 2.0% |
| Net margin | 21.8% | 2.4% | 9.3% | 2.3% | 5.1% | −2.1% | −0.1% | −3.5% | −17.0% | −3.8% | −4.5% | −6.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BVS's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BVS financial results
In fiscal year 2025 (ended December 31, 2025), Bioventus reported revenue of $568.1 million, down 0.9% from the year before. It had net income of $22.7 million, a net profit margin of 4.0%. Diluted earnings per share came to $0.68. Over five years revenue grew at an average rate of 12.1% a year.
See the BVS stock overview for the latest quote and news, or the BVS chart for price history and technical indicators.
BVS income statement FAQ
What is Bioventus's annual revenue?
Bioventus reported total revenue of $568.1 million for fiscal year 2025, which ended on December 31, 2025. That was down 0.9% from $573.3 million the previous year.
Is Bioventus profitable?
Yes. Bioventus reported net income of $22.7 million in fiscal 2025, a net profit margin of 4.0%; its operating margin was 10.3%.
What is Bioventus's gross margin?
Bioventus's gross margin was 67.3% in fiscal 2025: for every $100 of revenue, Bioventus kept $67 after the direct cost of its products and services.
How much does Bioventus spend on research and development?
Bioventus spent $12.1 million on research and development in fiscal 2025, 2.1% of revenue.
How fast is Bioventus growing?
Revenue grew 12.1% a year on average over the last five fiscal years, from $321.2 million to $568.1 million.
What are Bioventus's earnings per share?
Bioventus earned $0.68 per diluted share in fiscal 2025, compared with $0.47 a year earlier.
When will Bioventus report its next earnings?
Bioventus is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens.
When does Bioventus's fiscal year end?
Bioventus's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.